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Evolution and Revolution in CMR Imaging
Eike Nagel, MD, PHD,* Jagat Narula, MD, PHDzRevolution is a fundamental change that takes place
in a relatively short period of time.
Evolution is the change in characteristics over
successive generations. Evolutionary processes give rise
to diversity at every level of organization.n this issue of iJACC, we publish a review from
Salerno and Kramer on novel quantitative ap-
proaches for CMR. The report highlights the
drastic changes the ﬁeld is experiencing and will
continue to experience in the ensuing years. Tools,
which have been lingering around for several years
are now ready for clinical use, some of them waiting
for application and some of them with immediate
utility. To understand the power of this change it is
important to understand the dynamics of change in
the ﬁeld of CMR, which are different than in many
other ﬁelds of imaging and medicine.
CMR is a continuously evolving technique. While
with some imaging techniques the major changes
occur from changing the hardware (e.g. upgrade form
4- to 16- to 64-slice or beyond in CT, or from
M-mode to 2D and 3D in echocardiography), CMR
evolves in small steps with many parameters involved
in data acquisition, reconstruction, and post-
processing. Even the change from 1.5- to 3-T did
not lead to amajor change in practice.While this leads
to a wealth of new opportunities and continuous
expansion of possibilities and indications, it also leads
to a continuous technical drift with the danger of lack
of standardization and focus on technical issues rather
than on medical questions. Frequently this results in
questions from funders (“Is this a drift of a step-
change?”), reviewers (“Why did you not use the
recently technique published from our group?”), and
users (“Is it ready for clinical application?”).From the *Division of Imaging Sciences and Medical Engineering, King’s
College, London, United Kingdom; and the zIcahn School of Medicine at
Mount Sinai, New York, New York.CMR is a fully established technique in clinical
cardiology today. The main success for CMR today
is based on a “revolution” (such as the introduction
of late gadolinium enhancement imaging to detect
scar and ﬁbrosis in 1999) (1) as well as the “evolu-
tion” (such as perfusion techniques evolving into
robust clinical tools) (2–4). Both developments are
independent and offer strong risk predictors
providing excellent outcome data (5,6), allow robust
diagnostic accuracy (7), as well as incremental sup-
port to patient management (8).
We are now observing another “revolution” of
CMR, the change from visualization to quantiﬁca-
tion. Some of this has immediate clinical conse-
quences. The ﬁrst successful example of quantitative
tissue characterization with CMR was the develop-
ment, standardization, clinical validation, and wide
implementation of T2* measurements, leading to
completely new pathways of managing patients
(such as hemochromatosis by guiding their man-
agement on cardiac iron overload rather than liver
iron of blood values) (9,10). The success story of
T2* mapping shows several components which may
be important for the current developments in per-
fusion quantiﬁcation as well as T1 and T2 mapping.
First, T2* measurements had an immediate clinical
application. Second, the ﬁndings could be used to
guide patient management, as there was an efﬁcient
therapy. The impact of a measurement tool with no
application or an application with no efﬁcient ther-
apy would obviously have been much smaller. Third,
the success of T2* measurements was based on the
provision of normal and abnormal values for a given
imaging and post-processing pathway. It was (and
still is) more important that T2* measurements allow
to make therapeutic decisions, than whether it re-
ﬂects the true T2* or the true iron content. The
importance is that we know which value is normal
for a given scanner, sequence, and post-processing
tool, and what abnormal values mean.
Do we see similar conditions for the upcoming
tools? Perfusion quantiﬁcation has several immediate
clinical applications ranging from the decision on
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838revascularization based on presence and extent
rather than the pure presence of ischemia, to the
effective assessment of microvascular disease and
triple vessel disease. In addition, there are other
applications, such as follow-up, assessment of the
effectiveness of (drug) therapy, and risk stratiﬁca-
tion. It is not entirely understood whether there
is a truly effective therapy, and which patients
would beneﬁt from revascularization. While there
is good data that patients with no ischemia should
not be revascularized, there is much less evidence
on the contrary. Currently recruiting trials will
clarify whether patients with stable angina can
be guided noninvasively by perfusion imaging
(MR-INFORM) (11) and whether revasculariza-
tion of patients with moderate ischemiawould beneﬁt
from revascularization (https://www.ischemiatrial.org).
Absolute quantiﬁcation also suffers from the evolu-
tionary processes with multiple sequences and post-
processing algorithms. One way to overcome these
issues is by employing parameters that are based on
an internal standard, such as myocardial perfusion
reserve or transmural gradients.
T1 mapping also has some immediate clinical
applications, such as detection and grading of
amyloid disease and detection and risk assessment of
various cardiomyopathies as well as quantiﬁcation of
myocardial involvement in valvular disease. How-
ever, since T1 mapping provides novel information,which is not yet available in the current literature,
signiﬁcant work will be required to deﬁne its clini-
cal application. It will be important to focus on
providing the clinical evidence, rather than focusing
on technical development. This evidence will then
also guide us toward effective therapy, such as device
implantation, valve replacement, or the develop-
ment and utilization of drugs, which reduce or
reverse the development of myocardial ﬁbrosis at an
early stage.
T2 mapping is farthest away from immediate
clinical use. The assessment of edema will help to
understand the area at risk and diagnose acute in-
ﬂammatory diseases, such as myocarditis. However,
the former is mainly a research application and the
latter has no speciﬁc therapy following the diagnosis.
It is also important to understand the lack of a
gold standard for reference, unlike the utility of PET
or SPECT for the assessment of perfusion imaging.
For T1- and T2-mapping novel sequences may
be closer to T1 and T2 phantoms, thus measuring
these physical parameters more accurately, the more
important question, however, is how well they mea-
sure ﬁbrosis, differentiate into reversible and irre-
versible ﬁbrosis, measure water content, differentiate
into interstitial or intracellular water, and guide us
towards clinical decision making. The impact of a
revolution, even in a small ﬁeld, such as CMR may
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